Treatment of primary aldosteronism

被引:23
|
作者
Quinkler, Marcus [2 ]
Stewart, Paul M. [1 ]
机构
[1] Univ Birmingham, Queen Elizabeth Hosp, Div Med Sci, Inst Biomed Res, Birmingham B15 2TH, W Midlands, England
[2] Charite, D-10117 Berlin, Germany
关键词
primary aldosteronism; mineralocorticoid receptor; adrenalectomy; spironolactone; eplerenone; conn's adenoma; GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM; CONVERTING ENZYME-INHIBITOR; CALCIUM-CHANNEL BLOCKADE; INTIMA-MEDIA THICKNESS; PLASMA-RENIN ACTIVITY; ESSENTIAL-HYPERTENSION; PRIMARY HYPERALDOSTERONISM; RESISTANT HYPERTENSION; HYPER-ALDOSTERONISM; BLOOD-PRESSURE;
D O I
10.1016/j.beem.2010.10.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The prevalence of primary hyperaldosteronism approaches 10% of all hypertensive patients, and besides efficient diagnostic procedures, effective treatment is of increasing importance to reverse increased morbidity and mortality. Aldosterone-producing adenoma and unilateral adrenal hyperplasia are amenable to cure by endoscopic adrenalectomy. Bilateral adrenal hyperplasia (micro- or macronodular), which comprises two-thirds of primary hyperaldosteronism, is treated primarily by mineralocorticoid receptor antagonists (starting dose 12.5-25 mg/day spironolactone with titration up to 100 mg/day, alternatively 50-100 mg/day eplerenone). If blood pressure is not normalised by this first-line treatment, additional treatment with potassium-sparing diuretics (amiloride or triamterene) or calcium channel antagonists is necessary. The start of medication should be closely monitored by serum electrolyte and creatinine controls. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:923 / 932
页数:10
相关论文
共 50 条
  • [1] Treatment of primary aldosteronism: Where are we now?
    Karagiannis, Asterios
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2011, 12 (01) : 15 - 20
  • [2] Primary aldosteronism: emerging trends
    Galati, Sandi-Jo
    Hopkins, Sarah M.
    Cheesman, Khadeen C.
    Zhuk, Rachel A.
    Levine, Alice C.
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2013, 24 (09) : 421 - 430
  • [3] Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
    Stavropoulos, Konstantinos
    Papadopoulos, Christodoulos
    Koutsampasopoulos, Konstantinos
    Lales, Georgios
    Mitas, Christos
    Doumas, Michael
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (46) : 5508 - 5516
  • [4] Current diagnosis and treatment of primary aldosteronism
    Kaplan, Norman M.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2010, 8 (11) : 1527 - 1530
  • [5] Personalized Treatment of Patients With Primary Aldosteronism
    Obeid, Hiba
    Cardenas, Stanley M. Chen
    Khairi, Shafaq
    Turcu, Adina F.
    ENDOCRINE PRACTICE, 2023, 29 (06) : 484 - 490
  • [6] Benefits of Surgical Over Medical Treatment for Unilateral Primary Aldosteronism
    Ahmed, Sumaiya
    Hundemer, Gregory L.
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [7] The pharmacological treatment of primary aldosteronism
    Janmohamed, S
    Bouloux, PMG
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (05) : 563 - 573
  • [8] Diagnosis and management of primary aldosteronism
    Vilela, Leticia A. P.
    Almeida, Madson Q.
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2017, 61 (03): : 305 - 312
  • [9] How common is primary aldosteronism?
    Hundemer, Gregory L.
    Kline, Gregory A.
    Leung, Alexander A.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2021, 30 (03) : 353 - 360
  • [10] Targeted treatment of primary aldosteronism - The consensus of Taiwan Society of Aldosteronism
    Huang, Kuo-How
    Yu, Chih-Chin
    Hu, Ya-Hui
    Chang, Chin-Chen
    Chan, Chieh-Kai
    Liao, Shih-Cheng
    Tsai, Yao-Chou
    Chueh, Shih-Chieh Jeff
    Wu, Vin-Cent
    Lin, Yen-Hung
    Lin, Jui-Hsiang
    Wang, Wei-Jie
    Wu, Che-Hsiung
    Er, Leay Kiaw
    Chang, Chia-Hui
    Chang, Ya-Li
    Ho, Yi-Luwn
    Chang, Hung-Wei
    Lin, Lian-Yu
    Hu, Fu-Chang
    Liu, Kao-Lang
    Wang, Shuo-Meng
    Lu, Ching-Chu
    Yen, Ruoh-Fang
    Wu, Kwan-Dun
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2019, 118 (01) : 72 - 82